{"protocolSection": {"identificationModule": {"nctId": "NCT00350779", "orgStudyIdInfo": {"id": "0431-052"}, "secondaryIdInfos": [{"id": "MK0431-052"}, {"id": "2006_507"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)", "officialTitle": "A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Metformin and a PPARg Agonist"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-06-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2007-09-25", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-06-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-07-07", "studyFirstSubmitQcDate": "2006-07-07", "studyFirstPostDateStruct": {"date": "2006-07-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-05-13", "resultsFirstSubmitQcDate": "2009-05-13", "resultsFirstPostDateStruct": {"date": "2009-07-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-04-06", "lastUpdatePostDateStruct": {"date": "2017-05-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist combination therapy."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 262, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Sitagliptin", "interventionNames": ["Drug: sitagliptin", "Drug: rosiglitazone", "Drug: metformin", "Drug: glipizide"]}, {"label": "2", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Comparator: Placebo", "Drug: rosiglitazone", "Drug: metformin", "Drug: glipizide"]}], "interventions": [{"type": "DRUG", "name": "sitagliptin", "description": "Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.", "armGroupLabels": ["1"], "otherNames": ["Januvia"]}, {"type": "DRUG", "name": "Comparator: Placebo", "description": "Placebo to sitagliptin 100mg tablet each day for 54 weeks.", "armGroupLabels": ["2"]}, {"type": "DRUG", "name": "rosiglitazone", "description": "Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.", "armGroupLabels": ["1", "2"], "otherNames": ["Avandia"]}, {"type": "DRUG", "name": "metformin", "description": "Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.", "armGroupLabels": ["1", "2"]}, {"type": "DRUG", "name": "glipizide", "description": "Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)", "armGroupLabels": ["1", "2"], "otherNames": ["Glucotrol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in HbA1c (Hemoglobin A1C) at Week 18", "description": "HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent.", "timeFrame": "Baseline and 18 Weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in FPG (Fasting Plasma Glucose) at Week 18", "description": "Change from baseline at Week 18 is defined as Week 18 minus Week 0", "timeFrame": "Baseline and 18 Weeks"}, {"measure": "Change From Baseline in 2-hour PMG (Post-meal Glucose) at Week 18", "description": "Change from baseline at Week 18 is defined as Week 18 minus Week 0", "timeFrame": "Baseline and Week 18"}, {"measure": "Change From Baseline in HbA1c (Hemoglobin A1C) at Week 54", "description": "HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent.", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in FPG (Fasting Plasma Glucose) at Week 54", "description": "Change from baseline at Week 54 is defined as Week 54 minus Week 0", "timeFrame": "Baseline and Week 54"}, {"measure": "Change From Baseline in 2-hour PMG (Post-meal Glucose) at Week 54", "description": "Change from baseline at Week 54 is defined as Week 54 minus Week 0.", "timeFrame": "Baseline and Week 54"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient has type 2 diabetes mellitus\n* Patient is inadequately controlled while taking two oral antidiabetic medications\n\nExclusion Criteria:\n\n* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis\n* Patient required insulin therapy within the prior 3 months\n* Patient has been taking Byetta (R) (exenatide) within the prior 3 months", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "78 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "22742523", "type": "DERIVED", "citation": "Dobs AS, Goldstein BJ, Aschner P, Horton ES, Umpierrez GE, Duran L, Hill JS, Chen Y, Golm GT, Langdon RB, Williams-Herman DE, Kaufman KD, Amatruda JM, Ferreira JC. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. J Diabetes. 2013 Mar;5(1):68-79. doi: 10.1111/j.1753-0407.2012.00223.x."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf\n\nhttp://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients 18-78 years of age with T2DM and inadequate glycemic control (HbA1c \u22657.5 and \u226411.0%) who were on stable doses of rosiglitazone (\u22654 mg/day) and metformin (\u22651500 mg/day) after an up to 20-week dose-titration and stabilization period were eligible to enter the 54-week study.", "recruitmentDetails": "Phase III\n\nFirst Patient In: 29-Aug-06. Last Patient Enrolled: 23-Mar-07. Last Patient Last Visit: 27-May-08; 41 study centers worldwide", "groups": [{"id": "FG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}, {"id": "FG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with placebo to sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "170"}, {"groupId": "FG001", "numSubjects": "92"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "148"}, {"groupId": "FG001", "numSubjects": "71"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "21"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Patient Moved", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Non-compliance with study procedures", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}, {"id": "BG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with placebo to sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "92"}, {"groupId": "BG002", "value": "262"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.4", "spread": "8.8"}, {"groupId": "BG001", "value": "54.8", "spread": "9.5"}, {"groupId": "BG002", "value": "54.5", "spread": "9.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "74"}, {"groupId": "BG001", "value": "37"}, {"groupId": "BG002", "value": "111"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "96"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "151"}]}]}]}, {"title": "Race/Ethnicity", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "82"}, {"groupId": "BG001", "value": "51"}, {"groupId": "BG002", "value": "133"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "10"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "23"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "58"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "82"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "14"}]}]}]}, {"title": "HbA1c (Hemoglobin A1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.8", "spread": "1.0"}, {"groupId": "BG001", "value": "8.7", "spread": "1.0"}, {"groupId": "BG002", "value": "8.8", "spread": "1.0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in HbA1c (Hemoglobin A1C) at Week 18", "description": "HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the Week 0 HbA1c percent.", "populationDescription": "The Full Analysis Set (FAS) included all patients with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. For FAS patients with no data at Week 18, the last non-baseline observed measurement was carried forward to Week 18.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and 18 Weeks", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}, {"id": "OG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with placebo to sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "88"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.03", "lowerLimit": "-1.17", "upperLimit": "-0.90"}, {"groupId": "OG001", "value": "-0.31", "lowerLimit": "-0.50", "upperLimit": "-0.13"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment; baseline; prior anti-hyperglycemic therapy", "paramType": "Mean Difference (Net)", "paramValue": "-0.72", "ciPctValue": "95", "ciLowerLimit": "-0.95", "ciUpperLimit": "-0.49", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "0.87"}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG (Fasting Plasma Glucose) at Week 18", "description": "Change from baseline at Week 18 is defined as Week 18 minus Week 0", "populationDescription": "The Full Analysis Set (FAS) included all patients with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. For FAS patients with no data at Week 18, the last non-baseline observed measurement was carried forward to Week 18.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and 18 Weeks", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}, {"id": "OG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with placebo to sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "169"}, {"groupId": "OG001", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-30.7", "lowerLimit": "-35.5", "upperLimit": "-26.0"}, {"groupId": "OG001", "value": "-11.7", "lowerLimit": "-18.3", "upperLimit": "-5.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment; baseline; prior anti-hyperglycemic therapy", "paramType": "Mean Difference (Net)", "paramValue": "-19.0", "ciPctValue": "95", "ciLowerLimit": "-27.2", "ciUpperLimit": "-10.9", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "31.3"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hour PMG (Post-meal Glucose) at Week 18", "description": "Change from baseline at Week 18 is defined as Week 18 minus Week 0", "populationDescription": "The Full Analysis Set (FAS) included all patients with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. For FAS patients with no data at Week 18, the last non-baseline observed measurement was carried forward to Week 18.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 18", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}, {"id": "OG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with placebo to sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-59.9", "lowerLimit": "-67.1", "upperLimit": "-52.6"}, {"groupId": "OG001", "value": "-22.0", "lowerLimit": "-32.1", "upperLimit": "-12.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment; baseline; prior anti-hyperglycemic therapy", "paramType": "Mean Difference (Net)", "paramValue": "-37.9", "ciPctValue": "95", "ciLowerLimit": "-50.2", "ciUpperLimit": "-25.5", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "43.7"}]}, {"type": "SECONDARY", "title": "Change From Baseline in HbA1c (Hemoglobin A1C) at Week 54", "description": "HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent.", "populationDescription": "The Full Analysis Set (FAS) included all patients with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. For FAS patients with no data at Week 54, the last non-baseline observed measurement was carried forward to Week 54.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}, {"id": "OG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with placebo to sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "88"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.05", "lowerLimit": "-1.21", "upperLimit": "-0.89"}, {"groupId": "OG001", "value": "-0.28", "lowerLimit": "-0.50", "upperLimit": "-0.05"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment; baseline; prior anti-hyperglycemic therapy", "paramType": "Mean Difference (Net)", "paramValue": "-0.77", "ciPctValue": "95", "ciLowerLimit": "-1.04", "ciUpperLimit": "-0.50", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "1.04"}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG (Fasting Plasma Glucose) at Week 54", "description": "Change from baseline at Week 54 is defined as Week 54 minus Week 0", "populationDescription": "The Full Analysis Set (FAS) included all patients with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. For FAS patients with no data at Week 54, the last non-baseline observed measurement was carried forward to Week 54.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}, {"id": "OG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with placebo to sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "169"}, {"groupId": "OG001", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-28.0", "lowerLimit": "-33.3", "upperLimit": "-22.8"}, {"groupId": "OG001", "value": "-10.7", "lowerLimit": "-18.0", "upperLimit": "-3.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment; baseline; prior anti-hyperglycemic therapy", "paramType": "Mean Difference (Net)", "paramValue": "-17.4", "ciPctValue": "95", "ciLowerLimit": "-26.4", "ciUpperLimit": "-8.4", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "34.6"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hour PMG (Post-meal Glucose) at Week 54", "description": "Change from baseline at Week 54 is defined as Week 54 minus Week 0.", "populationDescription": "The Full Analysis Set (FAS) included all patients with a baseline value and \u22651 post-baseline value for this outcome. Data following glycemic rescue were treated as missing. For FAS patients with no data at Week 54, the last non-baseline observed measurement was carried forward to Week 54.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 54", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}, {"id": "OG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with placebo to sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-50.7", "lowerLimit": "-59.1", "upperLimit": "-42.4"}, {"groupId": "OG001", "value": "-16.6", "lowerLimit": "-28.2", "upperLimit": "-5.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment; baseline; prior anti-hyperglycemic therapy", "paramType": "Mean Difference (Net)", "paramValue": "-34.1", "ciPctValue": "95", "ciLowerLimit": "-48.4", "ciUpperLimit": "-19.9", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "51.0"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Sitagliptin 100 mg Data Through Week 18", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day).", "seriousNumAffected": 2, "otherNumAffected": 20}, {"id": "EG001", "title": "Placebo Data Through Week 18", "description": "The Placebo group includes data from patients randomized to receive treatment with placebo to sitagliptin 100 mg tablet once daily (blinded) in addition to ongoing treatment with open-label rosiglitazone 4 mg oral tablets (4 to 8 mg/day) and open-label metformin 500 mg oral tablets (\u22651500 mg/day).", "seriousNumAffected": 2, "otherNumAffected": 14}, {"id": "EG002", "title": "Sitagliptin 100 mg Data Through Week 54", "seriousNumAffected": 14, "otherNumAffected": 70}, {"id": "EG003", "title": "Placebo Data Through Week 54", "seriousNumAffected": 4, "otherNumAffected": 35}], "seriousEvents": [{"term": "Any Cardiac Disorders", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Any Ear And Labyrinth Disorders", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Any Hepatobiliary Disorders", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Biliary Colic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Any Infections And Infestations", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Any Injury, Poisoning And Procedural Complications", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 92}]}, {"term": "Lower Limb Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 92}]}, {"term": "Any Musculoskeletal And Connective Tissue Disorders", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Intervertebral Disc Protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Pain In Extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Any Neoplasms Benign, Malignant And Unspecified", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 92}]}, {"term": "Astrocytoma Malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 92}]}, {"term": "Basal Cell Carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 92}]}, {"term": "Breast Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Neurilemmoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Prostate Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Any Nervous System Disorders", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Cerebrovascular Accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Diabetic Neuropathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Any Psychiatric Disorders", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 92}]}, {"term": "Suicidal Ideation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 92}]}, {"term": "Any Renal And Urinary Disorders", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}, {"term": "Renal Colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 92}]}], "otherEvents": [{"term": "Any Gastrointestinal Disorders", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 92}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 92}]}, {"term": "Any General Disorders And Administration Site Conditions", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 92}]}, {"term": "Oedema Peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 92}]}, {"term": "Any Infections And Infestations", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 46, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 15, "numAtRisk": 92}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 18, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 92}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 28, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 92}]}, {"term": "Any Musculoskeletal And Connective Tissue Disorders", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 92}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 92}]}, {"term": "Any Nervous System Disorders", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 92}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 92}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 92}]}, {"term": "Any Respiratory, Thoracic And Mediastinal Disorders", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 92}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 92}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 170}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 92}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Non-serious adverse event results represent those events included in the primary safety analysis for this study (events occurred prior to initiation of glycemic rescue therapy). Site 0520039 was non-compliant with GDP, data was removed from analyses."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclsoure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Canada", "Hong Kong", "Italy", "Malaysia", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "D000077154", "term": "Rosiglitazone"}, {"id": "D000005913", "term": "Glipizide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M9023", "name": "Glipizide", "asFound": "Xylocaine", "relevance": "HIGH"}, {"id": "M1677", "name": "Rosiglitazone", "asFound": "Facility", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}